Recent Progress in Anti-Influenza Chemotherapy

摘要: Influenza virus infections in high risk individuals, such as infants, the elderly, and patients with cardiopulmonary disorders or immunocompromised states, cause severe manifestations which often result fatalities. The emergence of a new antigen type influenza A (H5N1) Hong Kong during 1997 1998 threatened possible pandemic infection. investigation for anti-influenza chemotherapies has progressed last decade whereas clinical trials compounds have been limited to amantadine, rimantadine ribavirin. Fusion inhibitors directly inhibit conformational change haemagglutinin (HA), protease cleavage HA HA1 HA2, RNA transcription cap formation mRNA antisense oligonucleotides targeted at PB2 (a part viral polymerase) reported, their development phases. Recently, 2 neuraminidase (NA) inhibitors, zanamivir oseltamivir (GS 4104), were used treatment influenza. Both agents showed promising results. polyoxometalate, PM-523, inhibits fusion between envelope cell membrane penetration into cells. This compound shown potent activity synergistic inhibitory combination ribavirin vitro vivo. Resistant strains zanamivir, PM-523 isolated. analysis mutation points these contributed antiviral mechanisms action mechanism resistance mutants compounds.